title: Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy.
abstract: Health care practitioners utilize the United States-Food and Drug Administration (US-FDA) pregnancy categorization (A, B, C, D, X) for making decision on the appropriateness of certain medications during pregnancy. Many non US-FDA approved medications are registered and marketed in Saudi Arabia. However, these medications do not have an assigned pregnancy risk categorization like those approved in the US. The objective of this review is to evaluate, report, and categorize the foetal risk associated with non-US-FDA approved medications registered by the Saudi Food and Drug Authority (S-FDA) according to the US-FDA pregnancy risk categorization system. We identified 109 non-US-FDA approved medications in the Saudi National Formulary (SNF) as of October 2007. We searched for data on functional or anatomical birth defects or embryocidal-associated risk using different databases and references. An algorithm for risk assessment was used to determine a pregnancy risk category for each medication. Out of 93 eligible medications, 73% were assigned category risk C, 10 medications (11%) were assigned category risk D, and 12 medications (13%) were assigned category risk B. Only three medications were judged to be safe during pregnancy based on the available evidence and were assigned category risk A. Inconsistencies in defining and reporting the foetal risk category among different drug regulatory authorities could create confusion and affect prescribing. We believe that standardization and inclusion of this information in the medication package insert is extremely important to all health care practitioners.
authors: Pharmacy Services Division, King Faisal Specialist Hospital & Research Centre, P.O. Box 3354, Riyadh 11211 (MBC #11), Saudi Arabia ; Alfaisal University, College of Medicine, P.O. Box 50927, Riyadh 11533, Saudi Arabia.
authors: Ahmed H
authors: AH
authors: Al-Jedai
authors: Sakra S
authors: SS
authors: Balhareth
authors: Roaa A
authors: RA
authors: Algain
keywords: Birth defect; Embryocidal effect; Functional or anatomical birth defects; Medications; Pregnancy; Teratogenicity
references: Int J Gynaecol Obstet. 1997 May;57(2):145-51
references: 9184951
references: FDA Consum. 2001 May-Jun;35(3):16-20
references: 11458544
references: Am J Med Genet C Semin Med Genet. 2011 Aug 15;157C(3):175-82
references: 21766440
references: S Afr Med J. 1991 Dec 7;80(11-12):594-5
references: 1745952
references: Asia Oceania J Obstet Gynaecol. 1990 Dec;16(4):357-62
references: 2099731
references: J Antimicrob Chemother. 1995 May;35(5):691-6
references: 7592184
references: J Antimicrob Chemother. 2006 Oct;58(4):811-5
references: 16916865
references: Ann Pharmacother. 1999 Jan;33(1):112-3
references: 9972395
references: Am J Obstet Gynecol. 2002 Aug;187(2):333-9
references: 12193921
references: Birth Defects Res A Clin Mol Teratol. 2007 Sep;79(9):627-30
references: 17663419
references: Acta Obstet Gynecol Scand. 2000 Mar;79(3):234-7
references: 10716307
references: Z Geburtshilfe Perinatol. 1985 Sep-Oct;189(5):232-4
references: 4072319
references: Drug Saf. 2002;25(12):885-92
references: 12241129
references: Obstet Gynecol. 2009 Jan;113(1):166-188
references: 19104374
references: J Matern Fetal Neonatal Med. 2006 Mar;19(3):189-92
references: 16690513
references: Am J Med Genet A. 2005 Jan 15;132A(2):130-5
references: 15578620
references: Reprod Toxicol. 2001 Nov-Dec;15(6):619-29
references: 11738515
references: Obstet Gynecol. 2002 Sep;100(3):465-73
references: 12220765
references: Invest Radiol. 1995 Mar;30(3):156-8
references: 7797413
references: Teratology. 1997 Mar;55(3):165-76
references: 9181670
references: Br J Anaesth. 1995 Jun;74(6):643-6
references: 7640116
references: Wien Klin Wochenschr. 1986 Sep 26;98(18):613-7
references: 3788179
references: Seishin Shinkeigaku Zasshi. 2003;105(9):1136-44
references: 14639936